A First-in-Human Phase 1 Dose Escalation and Expansion Study of the Oral CARD11-BCL10-MALT1 Signaling Pathway Inhibitor XL114 in Patients with Non-Hodgkin&#39;s Lymphoma

XL114 - Exelixis

Bert H. O'Neil; Willy Solis; Sofia Vidal-Cardenas; Shailaja Uttamsingh; Abhijeet Kumar

Nov 29, 2022